Journal of
Clinical Medicine and Research

  • Abbreviation: J. Clin. Med. Res.
  • Language: English
  • ISSN: 2141-2235
  • DOI: 10.5897/JCMR
  • Start Year: 2009
  • Published Articles: 102

Full Length Research Paper

Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon

Lijie Han
  • Lijie Han
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Huifang Zhao
  • Huifang Zhao
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Qingsong Yin
  • Qingsong Yin
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Lin Chen
  • Lin Chen
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Yongping Song
  • Yongping Song
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar
Xudong Wei*
  • Xudong Wei*
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Google Scholar


  •  Received: 08 July 2014
  •  Accepted: 17 April 2015
  •  Published: 30 April 2015

Abstract

Mantle cell lymphoma (MCL) is a highly aggressive non-Hodgkin's lymphoma with poor prognosis. This study aims to explore a new, safe approach for patients with recurrent refractory MCL. A total of six patients with recurrent refractory MCL were recruited. They all accepted thalidomide tablets (100 mg/day) orally every night, accompanied with interferon α-2b (3 million units, injected subcutaneously) every other day. The patients were followed up for 41, 25, 20, 30, 40 and 36 months, respectively, with a median follow-up time of 33 months (20 to 41 months). No severe adverse reactions occurred. For patients with recurrent refractory MCL, the combination of thalidomide and interferon α-2b showed a positive result to provide them a longer survival period with higher quality of life.

 

Key words: Recurrent refractory mantle cell lymphoma, thalidomide, interferon α-2b, combination, adverse reaction.